Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. (AGIO) Revenue
Annual & quarterly revenue history · segment & region breakdown
AGIO · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAgios Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.07B, an increase of 48.03% year-over-year from $0.05B in FY2025.
Revenue trend
2025 – 2011 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.05B | +$0.02B | +48.03% |
| 2024-12-31 | $0.04B | +$0.01B | +36.07% |
| 2023-12-31 | $0.03B | +$0.01B | +88.36% |
| 2022-12-31 | $0.01B | +$0.01B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | -$0.12B | -100.00% |
| 2019-12-31 | $0.12B | +$0.02B | +24.92% |
| 2018-12-31 | $0.09B | +$0.05B | +119.45% |
| 2017-12-31 | $0.04B | -$0.03B | -38.46% |
| 2016-12-31 | $0.07B | +$0.01B | +18.22% |
Compare revenue vs peers
BiotechnologyCompare AGIO revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Agios Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Agios Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Agios Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AGIO revenue · 4 questionsAGIO's trailing twelve-month (TTM) revenue is $0.07B. That is an increase of 48.03% year-over-year from $0.05B in FY2025.
▸ Source: FMP · Agios Pharmaceuticals, Inc. SEC filings · GAAP · Agios Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026